Related Experiment Video
Updated: May 26, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Targeting protein-trafficking pathways alters melanoma treatment sensitivity
Zhi-ming Huang1, Milka Chinen, Philip J Chang
1Department of Dermatology, University of California, San Francisco, CA 94115, USA.
Abstract:
Protein-trafficking pathways are targeted here in human melanoma cells using methods independent of oncogene mutational status, and the ability to up-regulate and down-regulate tumor treatment sensitivity is demonstrated. Sensitivity of melanoma cells to cis-diaminedichloroplatinum II (cDDP, cis-platin), carboplatin, dacarbazine, or temozolomide together with velaparib, an inhibitor of poly (ADP ribose) polymerase 1, is increased by up to 10-fold by targeting genes that regulate both protein trafficking and the formation of melanosomes, intracellular organelles unique to melanocytes and melanoma cells. Melanoma cells depleted of either of the protein-trafficking regulators vacuolar protein sorting 33A protein (VPS33A) or cappuccino protein (CNO) have increased nuclear localization of cDDP, increased nuclear DNA damage by platination, and increased apoptosis, resulting in increased treatment sensitivity. Depleted cells also exhibit a decreased proportion of intracellular, mature melanosomes compared with undepleted cells. Modulation of protein trafficking via cell-surface signaling by binding the melanocortin 1 receptor with the antagonist agouti-signaling protein decreased the proportion of mature melanosomes formed and increased cDDP sensitivity, whereas receptor binding with the agonist melanocyte-stimulating hormone resulted in an increased proportion of mature melanosomes formed and in decreased sensitivity (i.e., increased resistance) to cDDP. Mutation of the protein-trafficking gene Hps6, known to impair the formation of mature melanosomes, also increased cDDP sensitivity. Together, these results indicate that targeting protein-trafficking molecules markedly increases melanoma treatment sensitivity and influences the degree of melanosomes available for sequestration of therapeutic agents.
Insights
Targeting protein-trafficking pathways in melanoma cells enhances sensitivity to chemotherapy drugs like cisplatin. Manipulating these pathways affects melanosome formation and drug response, offering new therapeutic strategies.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Melanoma treatment sensitivity is often influenced by complex cellular mechanisms.
- Protein-trafficking pathways play a crucial role in cellular function and organelle formation, including melanosomes in melanoma cells.
Purpose of the Study:
- To investigate the impact of targeting protein-trafficking pathways on melanoma cell sensitivity to chemotherapy.
- To explore the relationship between protein trafficking, melanosome biogenesis, and drug response in melanoma.
Main Methods:
- Utilized gene depletion of protein-trafficking regulators (VPS33A, CNO) in human melanoma cells.
- Assessed drug sensitivity to platinum-based agents (cisplatin, carboplatin) and other chemotherapeutics (dacarbazine, temozolomide) with velaparib.
- Modulated cell-surface signaling via melanocortin 1 receptor (MC1R) and analyzed melanosome maturation.
- Examined the effect of genetic mutation in a protein-trafficking gene (Hps6) on drug sensitivity.
Main Results:
- Depletion of VPS33A or CNO significantly increased melanoma cell sensitivity (up to 10-fold) to chemotherapy, correlating with increased nuclear drug localization and DNA damage.
- Targeting protein trafficking reduced the proportion of mature intracellular melanosomes.
- Modulating MC1R signaling with agouti-signaling protein (antagonist) increased cisplatin sensitivity, while melanocyte-stimulating hormone (agonist) decreased sensitivity.
- Impairment of melanosome formation via Hps6 mutation also enhanced cisplatin sensitivity.
Conclusions:
- Targeting protein-trafficking pathways is a viable strategy to markedly enhance melanoma treatment sensitivity.
- Melanosome biogenesis and protein trafficking are critical determinants of melanoma cell response to chemotherapy.
- Modulation of these pathways offers potential for novel therapeutic interventions in melanoma treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy